- Home
- CNF vs CASI Comparison
CNF vs CASI Comparison
Compare CNF & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- CASI
- Stock Information
- Founded
- CNF 1999
- CASI 1991
- Country
- CNF China
- CASI China
- Employees
- CNF N/A
- CASI N/A
- Industry
- CNF Finance: Consumer Services
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- CASI Health Care
- Exchange
- CNF Nasdaq
- CASI Nasdaq
- Market Cap
- CNF 59.0M
- CASI 58.8M
- IPO Year
- CNF 2018
- CASI 1996
- Fundamental
- Price
- CNF $1.18
- CASI $2.62
- Analyst Decision
- CNF
- CASI Strong Buy
- Analyst Count
- CNF 0
- CASI 1
- Target Price
- CNF N/A
- CASI $6.00
- AVG Volume (30 Days)
- CNF 57.9K
- CASI 42.2K
- Earning Date
- CNF 02-27-2025
- CASI 11-15-2024
- Dividend Yield
- CNF N/A
- CASI N/A
- EPS Growth
- CNF N/A
- CASI N/A
- EPS
- CNF 0.24
- CASI N/A
- Revenue
- CNF $109,788,152.00
- CASI $22,055,000.00
- Revenue This Year
- CNF N/A
- CASI N/A
- Revenue Next Year
- CNF $13.09
- CASI $134.79
- P/E Ratio
- CNF $4.92
- CASI N/A
- Revenue Growth
- CNF 12.99
- CASI N/A
- 52 Week Low
- CNF $0.81
- CASI $2.05
- 52 Week High
- CNF $2.84
- CASI $8.19
- Technical
- Relative Strength Index (RSI)
- CNF 60.31
- CASI 38.56
- Support Level
- CNF $1.07
- CASI $2.44
- Resistance Level
- CNF $1.16
- CASI $2.76
- Average True Range (ATR)
- CNF 0.10
- CASI 0.29
- MACD
- CNF 0.02
- CASI 0.03
- Stochastic Oscillator
- CNF 81.08
- CASI 21.18
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.